Study of Antibiotic Utilization Measures and Control of ESBLs in China
A single-center, prospective, comparative, antibiotic intervention study for patients admitted to MICU1 and...
Brief Summary
Official Title: “Association of Antibiotic Utilization Measures and Control of Extended-spectrum β-lactamases (ESBLs) in MICU1 and MICU2 at Buddhist Tzu Chi General Hospital.”
A single-center, prospective, comparative, antibiotic intervention study for patients admitted to MICU1 and MICU2
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
- Study Primary Completion Date: June 2005
Detailed Clinical Trial Description
1. To determine the value of using β-lactamases inhibitors in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection after 12 months.
2. To compare the acquisition rates of ESBL producing E. coli or K. pneumoniae at MICU1 and MICU2 after 12 months
Intervention(s) in this Clinical Trial
- Drug: Third generation cephalosporins
Outcome Measures for this Clinical Trial
Primary Measures
- For both MICU1 and MICU2 (acquisition), all culture results will be collected and recorded, then analyzed to determine the ESBL acquisition rate and bacterial isolates (E. coli or K. pneumoniae).
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- All patients admitted or transferred to the ICU/burn units.
- Patients of either sex, 18 years of age or older.
Exclusion Criteria:
- Patient with hypersensitivity to penicillins, cephalosporins, and beta-lactamase inhibitors.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Wyeth is now a wholly owned subsidiary of Pfizer Industry
Overall Clinical Trial Officials and Contacts
Medical Monitor Study Director Wyeth is now a wholly owned subsidiary of Pfizer
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00488813
Study ID Number: 101441
ClinicalTrials.gov Identifier: NCT00488813
Health Authority: Taiwan: Department of Health
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00488813
